Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.

@article{Ganter2005DevelopmentOA,
  title={Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.},
  author={Brigitte Ganter and Stuart Tugendreich and Cecelia I. Pearson and Eser Ayanoglu and Susanne Baumhueter and Keith A. Bostian and Lindsay Brady and Leslie J Browne and John T Calvin and Gwo-Jen Day and Naiomi Breckenridge and Shane Dunlea and Barrett P. Eynon and Lindsay Furness and Joe Ferng and M. R. Fielden and Susan Y. Fujimoto and L F Gong and Christopher C. Hu and Radha Idury and Michael S B Judo and Kyle L. Kolaja and May D Lee and Christopher McSorley and James M Minor and Ramesh V. Nair and Georges Natsoulis and Peter Nguyen and Simone M. Nicholson and Hang Thi Nguyet Pham and Alan H Roter and Dongxu Sun and Siqi Tan and Silke Thode and Alexander M. Tolley and Antoaneta Vladimirova and Jian Yang and Zhiming M Zhou and Kurt Jarnagin},
  journal={Journal of biotechnology},
  year={2005},
  volume={119 3},
  pages={219-44}
}
Successful drug discovery requires accurate decision making in order to advance the best candidates from initial lead identification to final approval. Chemogenomics, the use of genomic tools in pharmacology and toxicology, offers a promising enhancement to traditional methods of target identification/validation, lead identification, efficacy evaluation, and toxicity assessment. To realize the value of chemogenomics information, a contextual database is needed to relate the physiological… CONTINUE READING